Found 87 results
[ Author(Desc)] Title Type Year
Filters: Author is Luiz E Bermudez  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
L. E. Bermudez, Sangari, F. J., Kolonoski, P., Petrofsky, M., and Goodman, J., The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells., Infection and immunity, vol. 70, no. 1, pp. 140-6, 2002.
L. E. Bermudez, Production of transforming growth factor-beta by Mycobacterium avium-infected human macrophages is associated with unresponsiveness to IFN-gamma., Journal of immunology (Baltimore, Md. : 1950), vol. 150, no. 5, pp. 1838-45, 1993.
L. E. Bermudez, [Post-antibiotic effect in the treatment of infections in neutropenic patients]., Revista do Hospital das Clínicas, vol. 41, no. 2, pp. 76-9, 1986.
L. E. Bermudez and Petrofsky, M., Host defense against Mycobacterium avium does not have an absolute requirement for major histocompatibility complex class I-restricted T cells., Infection and immunity, vol. 67, no. 6, pp. 3108-11, 1999.
L. E. Bermudez, Infection of "nonprofessional phagocytes" with Mycobacterium avium complex., Clinical immunology and immunopathology, vol. 61, no. 2 Pt 1, pp. 225-35, 1991.
L. E. Bermudez and Petrofsky, M., Regulation of the expression of Mycobacterium avium complex proteins differs according to the environment within host cells., Immunology and cell biology, vol. 75, no. 1, pp. 35-40, 1997.
L. E. Bermudez, Shelton, K., and Young, L. S., Comparison of the ability of Mycobacterium avium, M. smegmatis and M. tuberculosis to invade and replicate within HEp-2 epithelial cells., Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, vol. 76, no. 3, pp. 240-7, 1995.
L. E. Bermudez and Young, L. S., Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex., Journal of leukocyte biology, vol. 48, no. 1, pp. 67-73, 1990.
L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S., SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease., Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.
L. E. Bermudez, Kolonoski, P., Young, L. S., and Inderlied, C. B., Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection., Antimicrobial agents and chemotherapy, vol. 38, no. 8, pp. 1844-8, 1994.
L. E. Bermudez, Wu, M., and Young, L. S., Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin., The Journal of infectious diseases, vol. 156, no. 3, pp. 510-3, 1987.
L. E. Bermudez, Nash, K., Petrofsky, M., Young, L. S., and Inderlied, C. B., Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice., Antimicrobial agents and chemotherapy, vol. 44, no. 10, pp. 2619-22, 2000.